fenoldopam has been researched along with Kidney Failure, Chronic in 10 studies
Fenoldopam: A dopamine D1 receptor agonist that is used as an antihypertensive agent. It lowers blood pressure through arteriolar vasodilation.
Kidney Failure, Chronic: The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION.
| Excerpt | Relevance | Reference |
|---|---|---|
| "These results show that for advanced chronic renal failure, fenoldopam has diuretic and natriuretic properties that could be of clinical relevance." | 1.28 | Diuretic and natriuretic properties of fenoldopam in chronic renal failure. ( Alcázar, JM; Alvarez, C; Andrés, A; García-Robles, R; Martínez, J; Oliet, A; Rodicio, JL; Ruilope, LM; Sancho, J, 1989) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 5 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Stone, GW | 1 |
| McCullough, PA | 1 |
| Tumlin, JA | 1 |
| Lepor, NE | 1 |
| Madyoon, H | 1 |
| Murray, P | 1 |
| Wang, A | 1 |
| Chu, AA | 1 |
| Schaer, GL | 1 |
| Stevens, M | 1 |
| Wilensky, RL | 1 |
| O'Neill, WW | 1 |
| Cohen, MG | 1 |
| Ng, MK | 1 |
| Tremmel, J | 1 |
| Fitzgerald, PJ | 1 |
| Fearon, WF | 1 |
| Barr, LF | 1 |
| Kolodner, K | 1 |
| Robles, RG | 1 |
| Villa, E | 1 |
| Andres, A | 2 |
| Martinez, J | 2 |
| Ruilope, LM | 2 |
| Sancho, JM | 1 |
| Kini, AS | 1 |
| Mitre, CA | 1 |
| Kamran, M | 1 |
| Suleman, J | 1 |
| Kim, M | 1 |
| Duffy, ME | 1 |
| Marmur, JD | 1 |
| Sharma, SK | 1 |
| Girbes, AR | 1 |
| van Veldhuisen, DJ | 1 |
| Smit, AJ | 2 |
| de Fijter, CW | 1 |
| Comans, EF | 1 |
| de Vries, PM | 1 |
| Oe, PL | 1 |
| Roos, JC | 1 |
| Streurman, O | 1 |
| Donker, AJ | 1 |
| Brooks, DP | 1 |
| Goldstein, R | 1 |
| Koster, PF | 1 |
| DePalma, PD | 1 |
| DiCristo, M | 1 |
| Karpinski, K | 1 |
| Hyneck, M | 1 |
| García-Robles, R | 1 |
| Alcázar, JM | 1 |
| Alvarez, C | 1 |
| Oliet, A | 1 |
| Sancho, J | 1 |
| Rodicio, JL | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Renal Insufficiency Following Contrast Media Administration Trial II (Remedial II): The RenalGuard System in High-Risk Patients for Contrast-Induced Acute Kidney Injury[NCT01098032] | Phase 3 | 294 participants (Actual) | Interventional | 2009-01-31 | Completed | ||
| N-acetylcysteine and Fenoldopam Protect the Renal Function of Patients With Chronic Renal Insufficiency Undergoing Cardiac Surgery.[NCT00122018] | Phase 2 | 80 participants | Interventional | 2002-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The primary outcome measure will be the rate of development of CI-AKI in the 2 study arms (number of participants). CI-AKI is defined as an increase in the serum creatinine concentration >=0.3 mg/dL from the baseline value at 48 hours after administration of the contrast media or the need for dialysis. (NCT01098032)
Timeframe: at 48 hours following contrast exposure
| Intervention | participants (Number) |
|---|---|
| Systemic Alone Therapy Group | 146 |
| RenalGuard System Group | 146 |
2 trials available for fenoldopam and Kidney Failure, Chronic
| Article | Year |
|---|---|
Fenoldopam mesylate for the prevention of contrast-induced nephropathy: a randomized controlled trial.
Topics: Adult; Aged; Angiography; Angioplasty, Balloon, Coronary; Contrast Media; Creatinine; Dopamine Agoni | 2003 |
N-acetylcysteine and fenoldopam protect the renal function of patients with chronic renal insufficiency undergoing cardiac surgery.
Topics: Acetylcysteine; Aged; Cardiac Surgical Procedures; Dopamine Agonists; Double-Blind Method; Female; F | 2008 |
8 other studies available for fenoldopam and Kidney Failure, Chronic
| Article | Year |
|---|---|
First experience with intra-renal fenoldopam in a patient with heart failure.
Topics: Aged; Cardiac Catheterization; Catheterization; Electrocardiography; Equipment Design; Equipment Saf | 2005 |
Selective renal arterial infusion of fenoldopam for the prevention of contrast-induced nephropathy.
Topics: Acute Kidney Injury; Catheterization; Contrast Media; Fenoldopam; Humans; Kidney Failure, Chronic; M | 2006 |
Natriuretic effects of dopamine agonist drugs in models of reduced renal mass.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Adult; Aged; Animals; Blood Pressure; Di | 1993 |
Changing trends in incidence and predictors of radiographic contrast nephropathy after percutaneous coronary intervention with use of fenoldopam.
Topics: Aged; Atherectomy, Coronary; Cardiac Catheterization; Contrast Media; Diabetic Nephropathies; Dopami | 2002 |
Dopamine agonists, a new perspective in cardiovascular therapy?
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Deoxyepinephrine; Dopamine Agents; Fenol | 1991 |
The effect of fenoldopam on renal haemodynamics and natriuresis in chronic renal failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Adult; Aged; Aldos | 1990 |
Effect of fenoldopam in dogs with spontaneous renal insufficiency.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Administration, Oral; Animals; Creatinin | 1990 |
Diuretic and natriuretic properties of fenoldopam in chronic renal failure.
Topics: 2,3,4,5-Tetrahydro-7,8-dihydroxy-1-phenyl-1H-3-benzazepine; Blood Pressure; Diuresis; Dopamine Agent | 1989 |